AstraZeneca sharpens Imfinzi's lung cancer edge with big survival win

26th September 2018 Uncategorised 0

AstraZeneca already has an OK to market Imfinzi in stage 3 lung cancer that can’t be surgically removed. But just-unveiled survival data will strengthen its case—and its lead over its immuno-oncology rivals.

More: AstraZeneca sharpens Imfinzi's lung cancer edge with big survival win
Source: fierce